Table 2: Bone marker, BMD, and hormone data (mean ± SD). Patients with AN at admission (n) Patients with AN at 90% IBW (n) Amenorrheics at 90% IBW (n) Regained menses at 90% IBW (n) 8.1 ± 3.0 (33) 72.4 ± 32.7 (34) 1.05 ± 0.09 (37) 0.89 ± 0.15 (37) 0.91 ± 0.13 (37) 1.10 ± 0.15 (37) 244.4 ± 103.1 (34) 2.9 ± 2.7 (28) 2025 ± 748 (24) 1.4 ± 2.9 (30) 1.8 ± 2.1 (29) 23.7 ± 6.4 (32) 76.2 ± 36.7 (26) 153.1 ± 59.6 (25) 20.5 ± 5.5 (24) 2.0 ± 1.2 (23) 76.8 ± 18.3 (27) 1.0 ± 0.2 (27) 11.1 ± 5.9 (34) 70.9 ± 46.8 (30) 1.05 ± 0.09 (37) 0.94 ± 0.14 (37) 0.94 ± 0.12 (37) 1.09 ± 0.13 (37) 343.6 ± 120.1 (35) 14.7 ± 17.8 (31) 1567 ± 669 (25) 2.8 ± 2.8 (35) 2.7 ± 1.5 (34) 32.4 ± 14.0 (35) 81.8 ± 36.7 (31) 142.0 ± 81.1 (29) 16.7 ± 6.3 (27) 1.7 ± 1.0 (26) 106.0 ± 28.3 (32) 1.0 ± 0.2 (32) 11.4 ± 6.6 (25) 80.0 ± 50.3 (22) 1.04 ± 0.09 (27) 0.92 ± 0.14 (27) 0.93 ± 0.12 (27) 1.07 ± 0.14 (27) 345.7 ± 121.4 (26) 13.1 ± 15.6 (23) 1588 ± 654 (21) 2.5 ± 2.7 (25) 2.6 ± 1.3 (24) 28.2 ± 10.1 (25) 79.3 ± 38.6 (23) 139.8 ± 86.9 (23) 16.6 ± 5.9 (21) 1.9 ± 1.0 (21) 103.8 ± 27.8 (25) 1.0 ± 0.2 (25) 4 Characteristic Osteocalcina (ng/mL) Urine NTXb,d (nmol/mmol Cr) Total BMDb,c (g/cm2) Spine BMDa,b,c (g/cm2) Pelvis BMDa,b,c (g/cm2) Legs BMDb,c (g/cm2) IGF-1a,c (ng/ml) Leptina (ng/ml) Ghrelina (pg/ml) LHa,b (mIU/ml) FSHa,b(mIU/ml) Estradiola,b,c,d (pg/ml) Testosterone (ng/dl) DHEAS (µg/dl) Cortisola (µg/dl) TSH (mIU/L) Total T3a (ng/dl) Free T4b (ng/dl) Signiﬁcance set at P < 0.05 for all comparisons and is noted in the table. aSigniﬁcant diﬀerence between patients with AN at admission and patients with AN at 90% IBW. bSigniﬁcant diﬀerence between patients with AN at 90% IBW and controls. cSigniﬁcant diﬀerence between amenorrheics at 90% IBW and controls. dSigniﬁcant diﬀerence between amenorrheics at 90% IBW and regained menses at 90% IBW. who regained menses. Osteocalcin was also highest in this group, but not signiﬁcantly so. Compared to controls, the amenorrheic group at 90% IBW had lower BMI (P < 0.03), estradiol (P < 0.001), spine (P < 0.001), pelvis (P < 0.0005), leg (P < 0.008), and total (P < 0.001) BMDs and higher IGF-1 (P < 0.05). Signiﬁcant correlation between REE and change in spine BMD (r = 0.59, P < 0.02) was exhibited in the group who remained amenorrheic without correlation between REE and change in leg BMD (P < 0.09). Controlling for weight gain was limited by the number of patients in the group. No diﬀerence in BMI, estradiol, IGF-1, or BMDs was exhibited in the group who regained menses compared with 10.1 ± 3.6 (9) 45.9 ± 22.7 (8) 1.07 ± 0.06 (10) 0.98 ± 0.13 (10) 0.98 ± 0.09 (10) 1.12 ± 0.09 (10) 337.6 ± 123.2 (9) 19.3 ± 23.8 (8) 1835 ± 1213 (4) 3.6 ± 3.1 (10) 3.0 ± 1.8 (10) 42.7 ± 17.3 (10) 89.1 ± 31.8 (8) 150.2 ± 59.3 (6) 16.2 ± 7.6 (6) 1.2 ± 0.4 (5) 113.9 ± 30.9 (7) 1.0 ± 0.1 (7) Journal of Osteoporosis Controls (n) 8.7 ± 3.6 (12) 48.3 ± 14.4 (11) 1.13 ± 0.05 (16) 1.07 ± 0.09 (16) 1.07 ± 0.06 (16) 1.19 ± 0.07 (16) 247.9 ± 76.5 (12) 11.5 ± 5.9 (10) 1738 ± 542 (11) 4.0 ± 2.3 (13) 3.9 ± 1.3 (13) 52.4 ± 31.7 (14) 63.1 ± 21.0 (16) 175.8 ± 78.3 (16) 12.0 ± 4.3 (10) 1.9 ± 1.0 (12) 120.1 ± 22.9 (12) 1.1 ± 0.1 (12)